Trial Profile
Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 08 Oct 2018 Results published in the British Journal of Cancer
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
- 20 Dec 2017 Planned End Date changed from 30 Jun 2018 to 17 Jul 2018.